Co-administration of CART22-65s and huCART19 for B-ALL

NCT05674175 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

93

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia
B Lineage Lymphoblastic Lymphoma

Interventions

BIOLOGICAL: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
BIOLOGICAL: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Sponsor

Stephan Grupp MD PhD

Collaborators

[object Object]